Key Highlights

  • Humana (NYSE:HUM) rose 12.72% to USD 436.36 in the October 9, 2026 session, after federal regulators released 2027 Medicare Advantage Star Ratings on the evening of October 8.
  • The main catalyst is that its largest Medicare Advantage contract reportedly rose to 4 stars from 3.5 stars, which restores eligibility for quality Bonus payments tied to higher ratings.
  • Reportedly, the financial benefit arrives mainly in 2028 payments, and TD Cowen analyst Ryan Langston estimated a gain of USD 3 billion or more in 2028 revenue, an opinion and not a company figure.
  • Humana (NYSE:HUM) also traded sharply higher after hours on October 8, so the earlier jump and the October 9 session move overlap and should not be added together.

The Ratings Release Behind the Jump

Humana (NYSE:HUM) gained 12.72%, or USD 49.24, to USD 436.36 in the October 9, 2026 session on Volume of 2.502 million shares. Published reports tie the move to the 2027 Medicare Advantage Star Ratings, which the Centers for Medicare and Medicaid Services released on Thursday, October 8. Humana's largest contract moved up to 4 stars from 3.5 stars, according to published reports. Reports described a rise of about 13% in after-hours trading that evening, so that figure overlaps with the October 9 session and is not additive. No separate Humana release explaining the move was found, and an earlier article on this topic quoted a different session figure because it used a different price snapshot.

Why Half a Star Matters So Much

Medicare Advantage contracts rated 4 stars or higher qualify for quality bonus payments and larger rebates, which raise the funding an insurer receives per member. Humana's history shows the stakes: after its 2024 ratings, the share of its members in 4 star plans reportedly fell from 94% to 25% for the following year. Because ratings published now set payments for a later plan year, the 2027 ratings feed mostly into 2028 revenue, as reported. Rival Alignment Healthcare moved the other way as its largest contract slipped below 4 stars. The TD Cowen estimate of USD 3 billion or more in 2028 Revenue is unconfirmed and should be treated as one analyst's view, not as guidance from the company or the regulator.

Recent Results and What Could Go Wrong

In its July 29, 2026 results, Humana reported second quarter revenue of USD 40.87 billion, adjusted Earnings of USD 7.61 per share and GAAP earnings of USD 5.73 per share. It affirmed full-year adjusted earnings of at least USD 9.00 per share while lowering GAAP guidance to at least USD 6.52 from USD 8.36. The second quarter insurance benefit ratio was 91.2%, and full-year guidance is 92.75%, plus or minus 25 basis points. Risks include medical cost trends, the long wait until 2028 for bonus dollars, ratings methodology changes, and the chance that a rise of 12.72% already prices in much of the benefit. Humana (NYSE:HUM) also faces open enrollment, which starts October 15, as members choose plans for 2027.

Where Things Stand

Humana (NYSE:HUM) rose 12.72% in the October 9, 2026 session after the October 8 release of 2027 Star Ratings lifted its largest Medicare Advantage contract to 4 stars. The payoff is expected mostly in 2028, and analyst estimates are opinions. Watch open enrollment from October 15, medical cost trends and any company comment on the ratings. The stock is about 38.15% higher over 52 weeks.